Approval granted by South Korea's Ministry of Food and Drug Safety (MFDS) Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal ant...
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study Innovent Biologics, Inc. ("I...
What's Coming to ASCO 2026: Sneak Peek at Transformative Cancer Research The American Society of Clinical Oncology (ASCO) 2026 Annual Meet...
Asia-Pacific Phase 2 Study CBL-0206 Also Approved by Australia HREC and Taiwan TFDA, Accelerating Global Dual-Track Strategy U.S. ...
Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EU Novo Nordisk expects to launch Wegovy® 7.2 mg in a...
Joenja® (leniolisib) is first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS),...
New Biacore 8S and Biacore 8S+ systems combine rapid screening and high-quality molecular characterization in a single system Biacore Insight So...
Myosin Therapeutics, a clinical stage biotechnology company developing innovative therapies for oncology, announced that the first patient has been dosed...
OmicsHQ brings together comprehensive, expertly curated, standardized multi-omics datasets from across the scientific ecosystem, complete with pre-proces...
The state-of-the-art facility enhances support for complex modalities across all phases of drug development Key facts Thermo Fisher opens new bioanal...
Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced that it has received...
SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) announced that they have entered into an ...
Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B-Targeting Antibody Demonstrates Potential to Become a Bes...
The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s re...
© 2026 Biopharma Boardroom. All Rights Reserved.
